Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Doug Altman, founding director of the Centre for Statistics in Medicine and co-director of Oxford Clinical Trials Research Unit (OCTRU) at NDORMS has received The BMJ Lifetime Achievement Award 2015.

Dubbed the ‘Oscars’ of medicine, the annual awards showcase the best of British healthcare. The prestigious award, sponsored by GSK, is given to a doctor or medical researcher who has made an outstanding contribution to improving health or healthcare.

Professor Altman is an advocate for transparency in scientific research and has worked tirelessly over the last 20 years to develop essential tools for better design, analysis, clarity, and reporting of clinical and epidemiological research. Promoting the transparent and high quality reporting of evidence, Professor Altman has ultimately improved the care of patients.

The EQUATOR Network, of which he is co-founder, now provides essential resources for writing and publishing health research. huge online resource for every kind of study.

In addition, Professor Altman has encouraged, steered, and secured support for numerous international initiatives to improve reporting of health research. Through advocacy, education, and research, he has made a uniquely constructive contribution to improving the evidence base for clinical medicine and public health.

He was praised for his ability to inspire others, and his instrumental work challenging doctors, investigators, funders, journals, and institutions to do a better job with designing and communicating medical research.

His best-selling book, Practical Statistics for Medical Research, published in 1991, sold 50,000 copies in hardback and still sells today. “Almost every physician has seen or read his famous red book,” said friend and colleague, Professor Karl Moons, earlier this year.

Speaking of the award, Professor Altman says he was lucky to find what he really wanted to do – “I can look back and see the path I took but it was not visible ahead of me” – and is especially delighted to get this award in the field of medicine, not statistics, because the battle’s not yet won. But, thanks to him, it is well and truly joined.

Fiona Godlee, Editor-in-chief of the The BMJ, said Professor Altman “has done more than anyone else to encourage researchers to fully report what they actually did, warts and all, rather than letting the best be the enemy of the good or, worse, pretending that research is perfect.”

Professor Moons said in tribute that Altman had been “the convenor of almost every important guideline for transparent reporting in medical research.”

 

Photo copyright: Philippa Gedge Photography

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Three NIHR HTA grants awarded to Professor Tim Theologis

Congratulations to Professor Tim Theologis, who has been awarded three NIHR HTA grants to extend research in orthopaedic disorders in children.

Going straight to surgery found to be better than undergoing rehabilitation first for longstanding anterior cruciate ligament injury

New research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.